HLA-DOB Antikörper (N-Term)
-
- Target Alle HLA-DOB Antikörper anzeigen
- HLA-DOB (Major Histocompatibility Complex, Class II, DO beta (HLA-DOB))
-
Bindungsspezifität
- N-Term
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser HLA-DOB Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA
- Kreuzreaktivität
- Human
- Aufreinigung
- The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
- Immunogen
- Synthesized peptide derived from N-terminal of Human HLA-DOB.
- Isotyp
- IgG
- Top Product
- Discover our top product HLA-DOB Primärantikörper
-
-
- Applikationshinweise
- WB:1:500-1:3000,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- HLA-DOB (Major Histocompatibility Complex, Class II, DO beta (HLA-DOB))
- Andere Bezeichnung
- HLA-DOB (HLA-DOB Produkte)
- Synonyme
- DOB antikoerper, major histocompatibility complex, class II, DO beta antikoerper, HLA-DOB antikoerper, PATR-DOB antikoerper
- Hintergrund
-
Background: Important modulator in the HLA class II restricted antigen presentation pathway by interaction with the HLA-DM molecule in B-cells. Modifies peptide exchange activity of HLA-DM.
Tonnelle C., EMBO J. 4:2839-2847(1985).
Jonsson A.-K., Immunogenetics 29:411-413(1989).
Beck S., J. Mol. Biol. 228:433-441(1992).Aliases: HLA-DOBHLA class II histocompatibility antigen antibody, DO beta chain antibody, MHC class II antigen DOB antibody
- UniProt
- P13765
- Pathways
- Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-